相似文献
1
Serum p53 autoantibodies in patients with minimal lesions of ductal carcinoma in situ of the breast.
Br J Cancer. 1999 Oct;81(4):702-4. doi: 10.1038/sj.bjc.6690751.
2
[Prognostic significance of p53 autoantibodies in serum of patients with breast carcinoma].
Zentralbl Gynakol. 1996;118(10):560-4.
3
The significance of p53 autoantibodies in the serum of patients with breast cancer.
Anticancer Res. 1996 Mar-Apr;16(2):927-30.
4
Identification of a new panel of serum autoantibodies associated with the presence of in situ carcinoma of the breast in younger women.
Clin Cancer Res. 2009 Jul 15;15(14):4733-41. doi: 10.1158/1078-0432.CCR-08-3307. Epub 2009 Jul 7.
5
p53 overexpression is a predictor of local recurrence after treatment for both in situ and invasive ductal carcinoma of the breast.
J Surg Res. 2007 Jun 1;140(1):109-14. doi: 10.1016/j.jss.2006.10.045. Epub 2007 Feb 7.
6
Serum autoantibody signature of ductal carcinoma in situ progression to invasive breast cancer.
Clin Cancer Res. 2012 Apr 1;18(7):1992-2000. doi: 10.1158/1078-0432.CCR-11-2527. Epub 2012 Feb 9.
7
Cytosolic p53 protein and serum p53 autoantibody evaluation in breast cancer. Comparison with prognostic factors.
Anticancer Res. 1999 Nov-Dec;19(6B):5015-22.
8
Detection of serum autoantibodies to tumor suppressor gene p53 with a new enzyme-linked immunosorbent assay in patients with ovarian cancer.
Cancer Detect Prev. 2001;25(2):117-22.
9
The presence of serum anti-p53 antibodies from patients with invasive ductal carcinoma of breast: correlation to other clinical and biological parameters.
Breast Cancer Res Treat. 2005 Sep;93(2):111-5. doi: 10.1007/s10549-005-4321-9.
10
Microsatellite alterations on human chromosome 11 in in situ and invasive breast cancer: a microdissection microsatellite analysis and correlation with p53, ER (estrogen receptor), and PR (progesterone receptor) protein immunoreactivity.
J Surg Oncol. 2000 Jun;74(2):100-7. doi: 10.1002/1096-9098(200006)74:2<100::AID-JSO5>3.0.CO;2-O.
引用本文的文献
1
Can serum autoantibodies be a potential early detection biomarker for breast cancer in women? A diagnostic test accuracy review and meta-analysis.
Syst Rev. 2022 Oct 9;11(1):215. doi: 10.1186/s13643-022-02088-y.
2
Autoantibodies in Early Detection of Breast Cancer.
Cancer Epidemiol Biomarkers Prev. 2020 Dec;29(12):2475-2485. doi: 10.1158/1055-9965.EPI-20-0331. Epub 2020 Sep 29.
3
Evaluation of known oncoantibodies, HER2, p53, and cyclin B1, in prediagnostic breast cancer sera.
Cancer Prev Res (Phila). 2012 Aug;5(8):1036-43. doi: 10.1158/1940-6207.CAPR-11-0558. Epub 2012 Jun 19.
4
Early detection of breast cancer: new biomarker tests on the horizon?
Mol Diagn Ther. 2009 Dec 1;13(6):349-57. doi: 10.1007/BF03256340.
5
Application of protein microarrays for multiplexed detection of antibodies to tumor antigens in breast cancer.
J Proteome Res. 2008 Apr;7(4):1490-9. doi: 10.1021/pr700804c. Epub 2008 Feb 27.
本文引用的文献
1
Humoral immune response against p53 protein in patients with colorectal carcinoma.
Int J Cancer. 1997 Jan 6;70(1):46-51. doi: 10.1002/(sici)1097-0215(19970106)70:1<46::aid-ijc7>3.0.co;2-6.
2
[Antibody formation to cellular p53 protein in patients with squamous cell carcinomas of the upper respiratory and digestive system].
Laryngorhinootologie. 1996 Jan;75(1):53-6. doi: 10.1055/s-2007-997532.
3
The p53 gene in breast cancer: prognostic value of complementary DNA sequencing versus immunohistochemistry.
J Natl Cancer Inst. 1996 Feb 21;88(3-4):173-82. doi: 10.1093/jnci/88.3-4.173.
4
The relationship between serum p53 autoantibodies and characteristics of human breast cancer.
Br J Cancer. 1994 Jun;69(6):1115-9. doi: 10.1038/bjc.1994.219.
5
Prevalence of serum antibodies against the p53 tumor suppressor gene protein in various cancers.
Int J Cancer. 1994 Aug 15;58(4):480-7. doi: 10.1002/ijc.2910580404.
6
Prognostic significance of circulating P53 antibodies in patients undergoing surgery for locoregional breast cancer.
Lancet. 1995 Mar 11;345(8950):621-2. doi: 10.1016/s0140-6736(95)90523-5.
7
Microcalcifications associated with ductal carcinoma in situ: mammographic-pathologic correlation.
Semin Diagn Pathol. 1994 Aug;11(3):181-92.
8
Detection of antibodies against the cellular protein p53 in sera from patients with breast cancer.
Int J Cancer. 1982 Oct 15;30(4):403-8. doi: 10.1002/ijc.2910300404.
9
10
Screening for breast cancer in Nijmegen. Report of 6 screening rounds, 1975-1986.
Int J Cancer. 1989 Feb 15;43(2):226-30. doi: 10.1002/ijc.2910430209.
Zotero 插件